Valuation: NetraMark Holdings Inc.

Market Cap 77.91M 54.93M 48.17M 44.38M 41.07M 5.25B 79.38M 533M 207M 2.58B 207M 202M 8.93B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 77.91M 54.93M 48.17M 44.38M 41.07M 5.25B 79.38M 533M 207M 2.58B 207M 202M 8.93B EV / Sales 2026 *
194x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
President - 03/07/2022
Director of Finance/CFO 57 17/07/2022
Director TitleAgeSince
Chairman 40 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 54.9M
-1.41%+2.77%-22.98%+13.68% 2,888B
-1.60%+13.33%-4.96%+761.93% 322B
+1.84%-11.41%+289.04%+977.72% 128B
+0.81%-0.34%+16.78%+64.86% 102B
+1.67%+0.28%+71.31%+166.36% 91.41B
-0.49%-2.59%-19.02%+0.74% 83.61B
+1.04%+9.89%-30.31%+91.54% 63.84B
-2.49%+0.56%+3.65%+75.56% 47.86B
-2.80%+1.36%-48.85%+33.95% 40.6B
Average +0.16%+4.15%+28.30%+242.93% 418.73B
Weighted average by Cap. +0.01%+4.84%-7.43%+117.59%

Financials

2026 *2027 *
Net sales 401K 283K 248K 228K 211K 27.04M 409K 2.74M 1.07M 13.26M 1.06M 1.04M 45.97M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise